Embolotherapy Market Is Anticipated To Expand At A CAGR Of 8.4% By 2032

Currently estimated at US$ 3,545.56 billion, the worldwide embolotherapy market is expected to grow at a CAGR of 8.4% to reach US$ 7,942.8 billion by the end of 2032. Due to the rising incidence of cancer and the increased focus of the major players on technical breakthroughs, the market is anticipated to rise.

The monotherapy market is anticipated to increase over the course of the projected period as a result of rising investments in the construction of healthcare infrastructure, particularly in developing countries, and rising applications in end-use industries. When treating cancer, internal haemorrhages, aneurysms, and venous disorders, embolisation, a minimally invasive endovascular technique, is used to purposefully restrict blood flow in blood vessels.

Download a Sample Copy of This Report: –https://www.factmr.com/connectus/sample?flag=S&rep_id=8046?PJ 

Market Players: –

• Medtronic Plc.
• Stryker Corporation
• Johnson & Johnson
• BTG Plc.
• Cook Medical
• Penumbra Inc.
• Abbott Laboratories
• Boston Scientific Corporation
• Merit Medical Systems
• Terumo Corporation

Competitive Landscape

Medtronic plc, Stryker Corporation, Johnson & Johnson, BTG plc, Cook Medical, Penumbra, Inc., Abbott Laboratories, Boston Scientific Corporation, Merit Medical Systems, Terumo Corporation are some of the key companies in the embolotherapy market.

Companies operating in the market have been focusing on innovations. There is an immense focus on offering more efficient solutions depending upon evolving needs of end users. The global embolotherapy market is considered fairly fragmented due to the presence of a numerous players. Besides this, collaborations have been a key strategy among market players as they aim at expanding regional footprint as well as their product portfolio.

Some of the recent developments from the market are :

• In June 2022 -Stryker, today the opening of its new research and development facility, Stryker’s Global Technology Centre (SGTC) , at the International Tech Park. The 150,000-square-foot facility will help accelerate innovation in India and globally, and further support the company’s mission to make healthcare better.
• In September 2021 – Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Portico™ with FlexNav™ Transcatheter Aortic Valve Replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery. With this latest TAVR advancement, Abbott continues to offer the industry’s leading portfolio of structural heart solutions that include innovative, minimally invasive therapies to repair or replace diseased or damaged heart valves or close openings in the heart.
• In October 2022 – Biosense Webster, Inc., part of Johnson & Johnson MedTech, announced the European launch of the HELIOSTAR™ Balloon Ablation Catheter – the first radiofrequency balloon ablation catheter. The HELIOSTAR™ Balloon Ablation Catheter is indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) of the atria and, when used with a compatible multi-channel RF generator, for cardiac ablation.

Key Segments Covered in the Embolotherapy Market Industry Survey

• By Product Type :
  • Embolic Agents
    • Microspheres
    • Embolic coils
    • Embolic Plug Systems
    • Detachable Ballons
    • Liquid Embolic Agents,
    • others
  • Support Devices
    • Microcatheters
    • Guidewires
• By Disease Indication :
  • Cancer
    • Liver Cancer
    • Kidney Cancer
    • Other Cancer
  • Peripheral Vascular Disease
  • Peripheral Vascular Disease
  • Urological & Nephrological Disorder
  • Gastrointestinal Disorder
  • others
• By Procedure :
  • Transcatheter Arterial Embolization (TAE)
  • Transcatheter Arterial Radioembolization (TARE)/Selective Internal Radiation Therapy (SIRT)
  • Transarterial Chemoembolization (TACE)
• By End-user :
  • Hospitals& Clinics
  • Ambulatory Surgical Centre
  • Others

Regional analysis includes

• North America (U.S., Canada)
• Latin America (Brazil, Mexico, Argentina, Chile, Peru, Rest of LATAM)
• EU – (Germany, France, Italy, Spain), UK, BENELUX (Belgium, Netherlands, Luxemburg), NORDIC (Norway, Denmark, Iceland, Sweden), Eastern Europe (Poland, Ukraine, Czech Rep. etc.), Rest of Europe
• CIS & Russia
• Japan
• Asia Pacific Excluding Japan (Greater China, India, S. Korea, ASEAN Countries, Rest of APEJ)

How Fact.MR Assists in Making Strategic Moves?

The data provided in the Embolotherapy Market report offers comprehensive analysis of important industry trends. Industry players can use this data to strategize their potential business moves and gain remarkable revenues in the upcoming period.

The report covers the price trend analysis and value chain analysis along with analysis of diverse offering by market players. The main motive of this report is to assist enterprises to make data-driven decisions and strategize their business moves.

Customize this report for your specific research solution:https://www.factmr.com/connectus/sample?flag=RC&rep_id=8046?PJ 

Contact:

US Sales Office:

11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States

Tel: +1 (628) 251-1583

E-Mail : sales@factmr.com